Double maintains 1 strategies that include KRRO - Korro Bio, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VSEC | 40.19% | $2.18B | +76.94% | 0.47% |
VYGR | 35.77% | $302.08M | -27.33% | 0.00% |
MGTX | 33.64% | $474.39M | -9.67% | 0.00% |
QNRX | 33.42% | $2.08M | -89.00% | 0.00% |
LAC | 33.11% | $694.44M | -31.17% | 0.00% |
PKE | 32.20% | $296.29M | -4.92% | 3.37% |
AUTL | 29.51% | $609.41M | -61.51% | 0.00% |
LEU | 29.48% | $1.54B | +79.19% | 0.00% |
ALAR | 29.44% | $70.03M | -6.22% | 0.00% |
ACLX | 29.26% | $3.54B | +10.20% | 0.00% |
OKLO | 29.13% | $4.73B | +259.74% | 0.00% |
UUUU | 29.06% | $1.16B | -19.89% | 0.00% |
KYMR | 28.85% | $2.86B | +38.91% | 0.00% |
BEP | 28.61% | $5.93B | -20.76% | 6.73% |
CSCO | 27.77% | $247.85B | +18.92% | 2.57% |
BEPC | 27.70% | $9.34B | -11.70% | 5.68% |
MS | 27.44% | $222.00B | +56.56% | 2.60% |
BIP | 26.98% | $15.51B | +6.33% | 4.82% |
ARVN | 26.63% | $1.24B | -52.34% | 0.00% |
JYNT | 26.38% | $165.57M | +17.68% | 0.00% |
Finnhub
KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to advance additional pipeline...
Yahoo
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:45 p.m. PT (6:45 p.m. ET) at the Westin St. Francis in San Francisc
SeekingAlpha
Exciting potential in Korro Bio, Inc.'s non-viral gene editing platform as they enter clinical trials with a strong cash position. Click for our KRRO stock update.
Yahoo
Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein coding genesCAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein l
Finnhub
CAMBRIDGE - Korro Bio, Inc. , a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that...
Yahoo
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tue
Current Value
$37.991 Year Return
Current Value
$37.991 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NTZ | -22.80% | $57.28M | -16.80% | 0.00% |
PENG | -18.40% | $1.11B | -5.04% | 0.00% |
LRN | -16.68% | $5.19B | +100.52% | 0.00% |
SVC | -16.24% | $453.28M | -65.17% | 15.24% |
VHC | -11.27% | $33.26M | +45.99% | 0.00% |
NVAX | -11.07% | $1.53B | +132.93% | 0.00% |
CYCN | -10.94% | $7.90M | -3.80% | 0.00% |
OFG | -10.80% | $1.99B | +14.67% | 2.31% |
K | -9.98% | $28.19B | +49.68% | 2.77% |
BTCT | -9.66% | $37.49M | +84.20% | 0.00% |
CNK | -9.05% | $3.60B | +109.31% | 0.00% |
ROL | -9.04% | $23.55B | +13.04% | 1.27% |
PULM | -9.02% | $25.16M | +279.53% | 0.00% |
EW | -8.27% | $40.65B | -6.28% | 0.00% |
DAO | -8.06% | $217.37M | +102.33% | 0.00% |
CBOE | -7.66% | $21.11B | +6.85% | 1.18% |
SPOT | -7.62% | $98.17B | +134.15% | 0.00% |
ZCMD | -7.58% | $35.38M | -56.76% | 0.00% |
IBKR | -7.20% | $22.71B | +130.54% | 0.40% |
COST | -6.90% | $418.22B | +38.57% | 0.48% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LLYVA | <0.01% | $6.37B | +91.93% | 0.00% |
BW | 0.01% | $144.30M | +11.68% | 0.00% |
SUPV | 0.03% | $1.35B | +274.78% | 0.98% |
LYV | 0.03% | $32.09B | +55.02% | 0.00% |
OKTA | 0.06% | $15.09B | +4.21% | 0.00% |
STG | 0.07% | $36.34M | -25.99% | 0.00% |
GUG | 0.07% | - | - | 9.11% |
SNPS | 0.08% | $85.26B | +2.77% | 0.00% |
DLNG | -0.08% | $193.58M | +97.74% | 0.92% |
LX | -0.10% | $847.12M | +213.33% | 2.03% |
ES | 0.11% | $20.60B | +2.50% | 5.11% |
CABO | 0.12% | $1.90B | -38.89% | 3.48% |
FNKO | 0.13% | $681.71M | +76.64% | 0.00% |
IRS | -0.13% | $1.15B | +80.77% | 10.77% |
LQDT | 0.16% | $1.11B | +107.11% | 0.00% |
LICY | 0.16% | $31.64M | -69.85% | 0.00% |
TLRY | -0.16% | $1.05B | -43.72% | 0.00% |
HUM | -0.17% | $35.38B | -17.32% | 1.21% |
FRHC | 0.18% | $8.34B | +75.55% | 0.00% |
OSPN | 0.18% | $748.80M | +83.69% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IWC | 27.45% | $982.44M | 0.6% |
XPH | 27.18% | $167.55M | 0.35% |
PINK | 26.75% | $142.14M | 0.5% |
URA | 26.29% | $3.57B | 0.69% |
XSHD | 25.03% | $66.43M | 0.3% |
IWN | 24.37% | $12.32B | 0.24% |
VTWO | 24.29% | $12.78B | 0.1% |
IBB | 24.22% | $6.39B | 0.45% |
IWM | 24.21% | $73.87B | 0.19% |
SYLD | 23.81% | $1.28B | 0.59% |
QAI | 23.65% | $693.80M | 0.91% |
URNJ | 23.56% | $266.60M | 0.8% |
GSSC | 23.51% | $546.06M | 0.2% |
PBW | 23.46% | $301.51M | 0.65% |
CALF | 23.34% | $8.06B | 0.59% |
KOMP | 23.28% | $2.20B | 0.2% |
LDEM | 23.17% | $30.08M | 0.17% |
BSVO | 23.11% | $1.57B | 0.47% |
QCLN | 23.08% | $542.12M | 0.59% |
IWO | 23.05% | $13.09B | 0.24% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLOT | -19.56% | $8.12B | 0.15% |
VIXY | -14.16% | $195.31M | 0.85% |
TAIL | -12.71% | $64.78M | 0.59% |
VRIG | -12.01% | $1.21B | 0.3% |
CANE | -8.67% | $11.96M | 0.29% |
BILZ | -7.80% | $631.56M | 0.14% |
TBIL | -6.71% | $4.85B | 0.15% |
FBY | -6.33% | $168.28M | 0.99% |
PWZ | -5.85% | $710.13M | 0.28% |
CTA | -5.65% | $569.44M | 0.76% |
WEAT | -5.40% | $123.99M | 0.28% |
UNG | -5.35% | $664.75M | 1.06% |
SMB | -4.70% | $273.21M | 0.07% |
CLOI | -4.46% | $816.76M | 0.4% |
TPMN | -4.06% | $34.23M | 0.65% |
BILS | -3.79% | $3.36B | 0.1356% |
DBA | -3.77% | $828.49M | 0.93% |
XBIL | -3.37% | $653.80M | 0.15% |
AGZ | -2.91% | $718.22M | 0.2% |
DFNM | -2.74% | $1.45B | 0.17% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
MINT | -0.08% | $12.26B | 0.35% |
CNBS | 0.09% | $11.65M | 0.77% |
AGGH | -0.18% | $259.80M | 0.29% |
HYMU | -0.26% | $273.82M | 0.35% |
UTWO | -0.30% | $389.72M | 0.15% |
CGSM | -0.33% | $573.90M | 0.25% |
AGZD | 0.38% | $148.70M | 0.23% |
PHDG | 0.40% | $116.12M | 0.39% |
IBTI | -0.41% | $888.84M | 0.07% |
FTGC | 0.42% | $2.39B | 1.02% |
MUST | -0.45% | $423.28M | 0.23% |
XLP | -0.47% | $16.35B | 0.09% |
HYMB | -0.48% | $2.82B | 0.35% |
SCHP | 0.51% | $11.53B | 0.03% |
VTIP | -0.52% | $12.13B | 0.04% |
LGOV | 0.58% | $634.44M | 0.67% |
MUB | -0.59% | $40.41B | 0.05% |
CGSD | -0.59% | $955.40M | 0.25% |
USDU | 0.67% | $397.66M | 0.5% |
GOVT | -0.69% | $29.44B | 0.05% |